Search company, investor...


Founded Year



Loan | Alive

Total Raised




Last Raised

$1.5M | 3 yrs ago


Regenesis is engaged in the development, manufacturing, and sale of biomedical devices that promote healing and skin wound closure more quickly and cost-effectively than existing standards of wound treatment. The company's devices are based on its Cell Proliferation Induction (CPI) technology, in which electromagnetic signals trigger the repair and regeneration of soft tissue cells.

Headquarters Location

5301 N Pima Rd

Scottsdale, Arizona, 85250,

United States


Missing: REGENESIS BIOMEDICAL's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: REGENESIS BIOMEDICAL's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing REGENESIS BIOMEDICAL

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

REGENESIS BIOMEDICAL is included in 3 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



1,904 items


Medical Devices

413 items - excludes those without working websites.


REGENESIS BIOMEDICAL has filed 16 patents.

The 3 most popular patent topics include:

  • Inflammations
  • Medical treatments
  • Pseudoscience
patents chart

Application Date

Grant Date


Related Topics




Cosmetics, Inflammations, Personal hygiene products, Radiation therapy, Pesticides


Application Date


Grant Date



Related Topics

Cosmetics, Inflammations, Personal hygiene products, Radiation therapy, Pesticides




Arizona Business Leaders Reach Out In Support of SBIR/STTR Reauthorization

Jul 23, 2022

Posted on Forty-eight Arizona business leaders signed on to a letter delivered on July 22, 2022 to Arizona’s Congressional Delegation emphasizing the importance of reauthorizing the SBIR/STTR program. The letter, was signed by business leaders from: Arizona Bioindustry Association, Inc. (AZBio), Arizona Chamber of Commerce & Industry, Arizona Commerce Authority, Arizona Technology Council, Desert Angels, Inc., Greater Phoenix Chamber, Greater Phoenix Economic Council, Greater Phoenix Leadership, PHX East Valley Partnership, Southern Arizona Leadership Council (SALC), Tucson Metro Chamber, UAVenture Capital, University of Arizona, AdviNow Medical, Aesthetics Biomedical, Inc., Aqualung Therapeutics, Anuncia Medical, Inc., Beacon Biomedical, Becton Dickinson (BD), Biosensing Instrument, Inc., bioSyntagma, Inc., Calviri, Inc., Dignity Health, EthiX Associates, Exact Sciences, GT Medical Technologies, Inc., HonorHealth Research & Innovation Institute, Humabiologics, Inc., Langham Logistics, Inc., Mayo Clinic, Metfora, Microvascular Therapeutics, Navi Nurses, NuvOx Pharma, nVector, Plaza Companies, Regenesis Biomedical, Inc., Regional Center for Border Health, Inc.,  ReSuture Inc., SARRC, Scintillation Nanotechnologies, Inc., Sequitur Health Corp., SpencerFane, Translational Sciences, Inc.,  VMAS Solutions, Inc. (dba TouchPoint Solution), and Yelton and Associates. Since its inception in 1982, the SBIR/STTR program has supported our small business community as we work to improve health, develop new agricultural techniques, innovate for our national defense, explore space, and more. Across the agencies that participate in this essential program, Arizona small businesses have received 3,488 awards and over $1 billion in funding for research programs intended to meet the needs of these agencies, our country, and our people. Since the last SBIR/STTR reauthorization in 2016, 190 Arizona Small Businesses have received 623 awards totaling just under $268 million. The Small Business Innovation Research (SBIR) 3.2% set aside and the Small Business Technology Transfer (STTR) 0.45% set aside makes it possible for small, entrepreneurial firms to contribute their innovation talents to address defined needs of these agencies. SBIR/STTR ensures that small business has the opportunity to be part our country’s research and development enterprise. Based on review of the Arizona specific dataset of SBIR/STTR awards for the period from 2017 to 2021, our small business community’s highest award concentrations are with the Department of Defense (50%), NASA (16%), Department of Energy (10%), Health & Human Services (8%), and the National Science Foundation (7%). While many of these R&D programs are components that support larger agency program requirements, Arizonans’ work on NIH/HHS related programs illustrate projects that are designed to directly impact some of our greatest health challenges. Some examples of these developing health innovations include: Avery Therapeutics, a University of Arizona spin out company, is developing and engineered cardiac tissue for treating damaged or diseased hearts. Aqualung Therapeutics has begun human clinical trials in an effort to save lives for those afflicted with Acute Respiratory Distress Syndrome (ARDS). Biomotum is developing of a robotic ankle assist device to improve mobility in individuals with movement disorders Calviri, an Arizona State University spin out company, is developing a blood test for the early detection of cancers. CND Life Sciences has developed an accurate, evidence-based tool to help confirm a diagnosis of neurodegenerative disorders. Metfora is working to commercialize a blood test for diagnosing lung diseases based on the analysis of metabolites. Regulonix, a University of Arizona spin out company, is developing better therapeutics to treat chronic pain. SBIR/SSTR funding for health innovation is rarely sufficient to sustain the full development process let alone commercialization, but it can move the discovery process forward and begin the development process. The remaining stages require private sector partnerships and investments that are much greater than at the early R&D stage. Without SBIR/STTR funding, many potential health innovations won’t make it to commercialization. Innovative Arizona small businesses depend on the SBIR/STTR programs to address the research needs of our federal agencies. As they move their innovations forward, they grow their businesses, create jobs, and contribute to Arizona’s economy. A Defense Department assessment showed the SBIR/STTR Program has generated a 22:1 return for every federal dollar spent, and a study by the National Academy of Sciences found a commercialization rate of between 50-60% for SBIR/STTR investments-a win-win for the U.S. economy and taxpayer. Allowing even a short disruption of these programs could have negative consequences for high-tech small businesses that thrive on stability and predictability to budget and plan for the future – especially as we all work together to emerge from the COVID-19 pandemic and overcome the economic challenges it triggered.

REGENESIS BIOMEDICAL Frequently Asked Questions (FAQ)

  • When was REGENESIS BIOMEDICAL founded?

    REGENESIS BIOMEDICAL was founded in 1996.

  • Where is REGENESIS BIOMEDICAL's headquarters?

    REGENESIS BIOMEDICAL's headquarters is located at 5301 N Pima Rd, Scottsdale.

  • What is REGENESIS BIOMEDICAL's latest funding round?

    REGENESIS BIOMEDICAL's latest funding round is Loan.

  • How much did REGENESIS BIOMEDICAL raise?

    REGENESIS BIOMEDICAL raised a total of $10.12M.

  • Who are the investors of REGENESIS BIOMEDICAL?

    Investors of REGENESIS BIOMEDICAL include Paycheck Protection Program, Solstice Capital, Desert Angels, Fulcrum Equity Partners, TGap Ventures and 6 more.

  • Who are REGENESIS BIOMEDICAL's competitors?

    Competitors of REGENESIS BIOMEDICAL include Biorez, MedShape, Acelity, Microfabrica, Calibra Medical and 16 more.

Compare REGENESIS BIOMEDICAL to Competitors

Transcutaneous Technologies

Developing, manufacturing, selling and exporting transcutaneousndevices which will put physiologically active substances intonsubcutaneous tissue applying the theory of electrophoresis. Developing, manufacturing, selling, exporting and importing cosmetic devices, health enhancement devices and medical devices. nnDeveloping, manufacturing, selling, exporting and importing cosmetics. All businesses that are incidental or related to the businesses stated nin the preceding items.

Tissue Regeneration Systems

Tissue Regeneration Systems (TRS) is commercializing a skeletal reconstruction and bone reconstruction technology for the fabrication of bioresorbable implants. These implants fully replace themselves with natural bone over time, leaving no residual implanted device; moreover, although the micro-architecture of these implants is porous for the facilitation of bone integration, they can nonetheless bear load and are strong enough to support function without the need for reinforcement from metal plates. Such structural integrity enables them to be used as an alternative to harvested, autologous bone that is fixed with metallic plates for complex skeletal reconstruction. TRS implants are also integrated with an osteoconductive coating that enhances bone regeneration and proliferation; powerful orthobiologics and bone-growing autologous cells will readily bind to this coating, allowing for a controlled biologic release to further accelerate bone formation.

Wadsworth Medical Technologies

Wadsworth Medical Technologies has developed a needle-less wound closure system known as the DermaLOC. The product uses next-generation adhesives and was originally designed for the MIT $50K Competition. The company was founded in 2005 by Dr. Andrew Fox, Dr. Daniel Risking and Jim Mills (Mr. Mills is no longer with the company).

NIR Diagnostics

NIR Diagnostics is developing a diagnostic device to quantitatively assess the progress of the wound healing process. Per the company, the device has the potential to be a more accurate, more rapid, and less expensive method of wound assessment compared to those currently on the market.

Perfuzia Medical

Perfuzia Medical is developing the next generation of medical devices for the treatment of chronic wounds.


Zeno Corporation is a Houston-based medical technology company engaged in the development of products using its patented ClearPoint technologyˆ as well as other products related to skin care.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.